Evaluation of the Procleix Ultrio Plus ID NAT assay for detection of HIV 1, HBV and HCV in blood donors.
BACKGROUND
The Procleix Ultrio Plusassay is a new-generation qualitative in vitro nucleic acid amplification test used to screen for human immunodeficiency virus type 1 (HIV-1) RNA, hepatitis C virus (HCV) RNA and hepatitis B virus (HBV) DNA in blood donors. This study was performed to compare the Procleix Ultrio assay with the new-generation Procleix Ultrio Plus Nucleic Acid Test (NAT) assays.


METHODS
Ten thousand three hundred and two donor samples were run in parallel for ID NAT using the Procleix Ultrio and the Procleix Ultrio Plus assay. Simultaneously, enzyme-linked immunosorbent assay testing was performed on an EVOLIS Walk away System for HIV, HCV, HBsAg and anti-HBc. Reactive samples were confirmed using polymerase chain reaction.


RESULTS
In the 10,302 samples tested during the study period, we identified 15 NAT yields, and all these revealed HBV DNA in the discriminatory assays. Eight of these were exclusive yields from the Ultrio Plus assay and the remaining seven cases were determined as HBV NAT yield, both by the Procleix Ultrio as well as the Ultrio Plus assays, i.e. "Combined" yields. No HCV or HIV 1 yields were detected during the study period by either of two assays.


CONCLUSIONS
With an overall yield rate of 1 in 687 and an exclusive yield rate of 1 in 1287, the Procleix Ultrio Plus assay proved to be highly sensitive in detecting occult HBV infections.
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi, India.
Raj Nath
RN
Makroo
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi, India.
Mohit
M
Chowdhry
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi, India.
Aakanksha
A
Bhatia
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi, India.
Minimol
M
Antony
Discriminatory assay; NAT yield; Procleix Ultrio Plus